New Orleans-based MiniVax Inc. will develop a monoclonal antibody treatment for Pneumocystis pneumonia under an agreement with the University of Rochester, whose scientists did the research on the antibody.

Pneumocystis pneumonia, or PCP, is a life-threatening, fungal respiratory infection that affects people with weakened immune systems, such as patients who have HIV/AIDS, organ transplant recipients and those undergoing chemotherapy.

The agreement marks an important milestone for MiniVax, according to the company. MiniVax specializes in the research and development of novel treatments for opportunistic infections.